In this context, a recent study showed that patients with the MetS were more likely to respond in a favorable manner to GLP-1 receptor agonist therapy (in that case, exenatide) than to a dipeptidyl peptidase 4 inhibitor [9]. The gene discussed is DPP4; the disease is metabolic syndrome.